Search
Now showing items 1-3 of 3
Targeting androgen receptor splicing in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2021-04-30)
Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
(AMER ASSOC CANCER RESEARCH, 2021-11-01)
PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed ...
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2021-02-15)
Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, ...